Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Prime Medicine (PRME) Accumulated Depreciation & Amortization (2021 - 2025)

Prime Medicine filings provide 5 years of Accumulated Depreciation & Amortization readings, the most recent being $7.3 million for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 19.47% to $7.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.3 million, a 19.47% increase, with the full-year FY2025 number at $7.3 million, up 19.47% from a year prior.
  • Accumulated Depreciation & Amortization hit $7.3 million in Q4 2025 for Prime Medicine, up from $5.4 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $7.3 million in Q4 2025 to a low of $200000.0 in Q3 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $1.4 million (2024), compared with a mean of $2.3 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 270.67% in 2022 and later increased 19.47% in 2025.
  • Prime Medicine's Accumulated Depreciation & Amortization stood at $600000.0 in 2021, then skyrocketed by 270.67% to $2.2 million in 2022, then surged by 109.22% to $4.7 million in 2023, then skyrocketed by 31.7% to $6.1 million in 2024, then increased by 19.47% to $7.3 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $7.3 million (Q4 2025), $5.4 million (Q3 2025), and $1.9 million (Q2 2025) per Business Quant data.